Dr Piero Olliaro is the head of intervention and implementation research at TDR. He has been with TDR since 1993, covering different functions in research and capacity building. Before joining TDR he had worked as general practitioner, hospital consultant, and as researcher in academia and the pharmaceutical private sector.
Through this range of experiences he has acquired skills spanning laboratory, pharmacology, clinical and field research in several poverty-related infectious diseases. Some of his main achievements include contributions to: the establishment of artemisinin combination therapy and the development of artesunate-amodiaquine and artesunate-mefloquine for malaria; the development of rifabutin and studies of gatifloxacin for tuberculosis; paromomycin and various combination therapies for visceral leishmaniasis, paromomycin for cutaneous leishmaniasis; the provision of evidence for various policy and guidelines through systematic reviews; the establishment of the Drug for Neglected Diseases initiative (DNDi) and the Europe and Developing Countries Clinical Trial Partnership (EDCTP). Current areas of work include helminths and dengue.
The Newton Abraham Lecture 2014, delivered by Professor Piero Olliaro, Newton Abraham Visiting Professor, University of Oxford.